CTRI/2021/03/032020尚未招募未知
Safety and feasibility of cellular therapy with CD45RA depletion for the prophylaxis of viral infections in Haplo-identical stem cell transplantation - NOT APPLICABLE
WellcomeDBT India Alliance0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients undergoing Haplo-identical stem cell transplantation
排除标准
- •1.CMV reactivation ( >3 log copy number by DNA PCR in whole blood) in pre-transplant testing
- •2.Creatinine clearance >60 ml/min
- •3.Left ventricular ejection fraction >40%
- •4.Total bilirubin <=3 times the upper limit
- •5.No on-going gram negative blood stream infection
- •6.Systolic blood pressure >100mmHg
研究者
相似试验
已完成
1 期
A novel cell therapy to treat patients with hepatitis C virus (HCV)infection.Hepatitis C virus infectionOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesInflammatory and Immune System - Normal development and function of the immune systemACTRN12610000067077Eric J Gowans15
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of the Therapeutic Antibody Felzartamab in Rejection Late After Kidney Transplantatioate active or chronic active antibody-mediated rejectionEUCTR2021-000545-40-DEMedical University of Vienna20
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of the Therapeutic Antibody Felzartamab in Rejection Late After Kidney Transplantatioate active or chronic active antibody-mediated rejectionEUCTR2021-000545-40-ATMedical University of Vienna22
招募中
1 期
Activated NK cell therapy to negate MRD in AML patientsAcute myeloid leukemia.C92.0Acute myeloblastic leukemiaIRCT20230801058996N3Shahid Beheshti University of Medical Sciences15
进行中（未招募）
1 期
Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyeliaTraumatic spinal cord injury, chronically established, associated with syringomyelia and neurological deficit considered irreversible.EUCTR2015-002383-16-ESFundación Investigación Biomédica Hospital Universitario Puerta de Hierro6